HOME >> BIOLOGY >> NEWS
Newly discovered protein may be key to muscular dystrophy

A defect in the action of a newly discovered protein may play a central role in muscular dystrophy, a disease of progressive muscle degeneration with no known cure.

Scientists at UCSF's Ernest Gallo Clinic and Research Center discovered in an animal model of the disease that during periods of intense muscle activity, muscles remain excited too long and degenerate if the protein fails to transport the neurotransmitter acetylcholine away from the nerve-muscle synapse. Muscle degeneration is the hallmark of muscular dystrophy, one of the most common genetic diseases.

The study was carried out in the roundworm, C. elegans, an animal which has provided early clues to the role of a number of important molecules in the human nervous system. The researchers expect that the protein, which they showed is an acetylcholine transporter, plays the same role in humans as it does in C. elegans, identifying a potential new route for treatment of muscular dystrophy.

The research is being reported in the August 19 issue of the journal Nature.

Normally, a nerve cell induces a muscle cell to contract by releasing the neurotransmitter acetylcholine at the synapse -- the junction where the two cells meet. Researchers have identified transporters for most neurotransmitters, such as serotonin, dopamine and glutamate. The transporters remove neurotransmitters from the synapse, in effect providing an "off" switch to the neurotransmitter's potent effects. It was thought that normal enzymatic breakdown of acetylcholine was so effective that a transporter wasn't needed to clear excess acetylcholine from the synapse. But the scientists found that during periods of intense muscle activity, a transporter must clear acetylcholine from the synapse.

"Discovering a transporter for acetylcholine was quite a surprise," said Steven McIntire, MD, PhD, UCSF assistant professor of neurology. "Identification of an acetylcholine transporter i
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
18-Aug-2004


Page: 1 2 3

Related biology news :

1. Newly identified master gene key in babys first breath
2. Newly designed nanoparticle quantum dots simultaneously target and image prostate tumors in mice
3. Newly grown kidneys can sustain life in rats
4. Newly discovered gene controls levels of bad cholesterol in mice
5. Newly identified gene linked to brain development
6. Newly cloned gene key to global adaptation of wheat
7. Newly identified genes may help predict outcome in childhood leukemia
8. Newly identified gene may halt fuzzy, moldy fruit
9. Newly found gene resistant to economically crippling wheat disease
10. Newly invented Endometrial Function Test (EFT®) solves the puzzle of unexplained infertility
11. Newly mapped enzyme could yield new treatments for female sexual dysfunction

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2019)... ... May 20, 2019 , ... The ASGCT Clinical Trials Finder is ... throughout the United States. Data curated daily from ClinicalTrials.gov ensures the most up-to-date and ... who volunteered to assist in the development of the ASGCT Clinical Trials Finder ...
(Date:5/15/2019)... , ... May 15, 2019 , ... ... process of histology wherein tissues are cut into ultra-thin two-dimensional slices, placed on ... in the context of the brain is that the brain is a highly ...
(Date:5/8/2019)... Texas (PRWEB) , ... May ... ... Gary Hutchinson has been accepted into Forbes Technology Council, an invitation-only community ... Inc. Verified Company, is a full-service biopharmaceutical cold chain engineering firm that ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... Calif. (PRWEB) , ... April 09, 2019 , ... ... services firm focused on increasing the capacity of life sciences organizations to accelerate ... Cloud Assurance platform in the past 12 months. , USDM’s ...
(Date:4/8/2019)... ... 2019 , ... US Capital Global Securities , an affiliate of US ... the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of ... sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific ... CARB-X has proceeded with a second stage of funding for Specific’s Reveal™ rapid ... is on top of the $1.7 million already awarded by CARB-X. The additional ...
(Date:3/23/2019)... , ... March 22, 2019 , ... ... collection, and analysis to a team of researchers at Nnamdi Azikiwe University in ... Dr. Nneka R. Agbokoba, PhD, of the Department of Medical Laboratory Sciences and ...
Breaking Biology Technology:
Cached News: